ClinVar Miner

Submissions for variant NM_000335.4(SCN5A):c.3305C>A (p.Ser1102Tyr) (rs7626962)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 21
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000621429 SCV000735107 benign Cardiovascular phenotype 2017-07-12 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: General population or subpopulation frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance
Biesecker Lab/Clinical Genomics Section,National Institutes of Health RCV000171820 SCV000050842 benign Cardiac arrhythmia 2013-06-24 criteria provided, single submitter research
Cardiovascular Biomedical Research Unit,Royal Brompton & Harefield NHS Foundation Trust RCV000058563 SCV000090083 not provided not provided no assertion provided literature only This variant has been reported in the following publications (PMID:12193783;PMID:15161528;PMID:19841300;PMID:20129283).
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000058563 SCV000609588 benign not provided 2017-04-24 criteria provided, single submitter clinical testing
Color RCV000771119 SCV000902837 benign Arrhythmia 2018-03-19 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000041615 SCV000333275 benign not specified 2015-08-10 criteria provided, single submitter clinical testing
Equipe Genetique des Anomalies du Developpement,Université de Bourgogne RCV000755696 SCV000883128 benign Long QT syndrome 3 2018-11-21 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000396768 SCV000444013 likely benign Sick sinus syndrome 2016-06-14 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000304064 SCV000444014 likely benign Progressive familial heart block 2016-06-14 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000363449 SCV000444015 likely benign Romano-Ward syndrome 2016-06-14 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000273107 SCV000444016 likely benign Long QT syndrome 2016-06-14 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000204216 SCV000444017 likely benign Brugada syndrome 2016-06-14 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000368908 SCV000444018 likely benign Paroxysmal familial ventricular fibrillation 2016-06-14 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000274325 SCV000444019 likely benign Dilated Cardiomyopathy, Dominant 2016-06-14 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000058563 SCV000700031 likely benign not provided 2017-03-13 criteria provided, single submitter clinical testing Variant summary: The SCN5A variant, c.3308C>A (p.Ser1103Tyr) alters a conserved nucleotide and results in a replacement of a small size and polar Serine (S) with a large size and aromatic (Y). The variant was found predominantly in the African subcohort of the ExAC project at an allele frequency of 9.7% which exceeds ~973 times the maximal expected allele frequency of a disease causing SCN5A variant (0.01%) indicating neutrality. Moreover, 29 homozygote occurrences are also recorded in ExAC further supporting a benign outcome. Multiple case-control studies showed the variant to be overrepresented in African patient population (with ARYTH and SIDS) compared to control population (Splawski_2002; Sun_2002; Burke_2005; Plant_2006; Van Norstrand_2008). However, the odds ratios from these studies are not considerably high enough to definitely assort the variant as a risk factor. In addition, other SNPs observed in patients carrying this variant could also be considered playing a role as a risk of arrhythmia (Jeff_2011). From Splawski_2002: We estimate that 4.6 million African Americans carry Y1102. Most of these individuals will never have an arrhythmia because the effect of Y1102 is subtle. However, in the setting of additional acquired risk factors, particularly common factors such as medications, hypokalemia, or structural heart disease, these individuals are at increased risk. Successful strategies for prevention, including avoidance of certain medications, maintenance of a normal serum potassium concentration, and beta-blocker therapy, are available. Additional, longitudinal studies will be required to confirm the predictive utility of Y1102. Akylbekova_2014 demonstrated that SCN5A-1103Y has opposing effects on the two sub-components of the QT interval, with shortening of QRS duration and prolongation of the JT interval, thus SCN5A-1103Y genotype may provide information about myocardial repolarization beyond that provided by QTc prolongation. Jef_2011 showed that S1103Y was associated with P wave and PR durations (p<1.0105), but there was no other association at p<1.0104 with other ECG traits, including QT interval duration. Functional studies (Splawski_2002; Plant_2006) showed some impact on channel activity. Clinical laboratories classify variant as Benign/Likely benign/Uncertain Significance via ClinVar. Considering all evidence, the variant is unlikely to be pathogenic on its own, therefore it was classified as a "likely benign."
Invitae RCV000204216 SCV000262107 benign Brugada syndrome 2018-01-23 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000041615 SCV000065311 benign not specified 2018-02-09 criteria provided, single submitter clinical testing p.Ser1103Tyr in exon 18 of SCN5A: This variant was present in 8% (1903/23560) of African chromosomes by the Genome Aggregation Database, including 91 homozygote s (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs7626962). This variant is c lassified as benign for Mendelian disorders based upon frequency in the general population. There is some evidence that this variant could be a risk allele for arrhythmia, although this association has not been substantiated. ACMG/AMP Crite ria applied: BA1
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease,Montreal Heart Institute RCV000845517 SCV000987620 risk factor Left ventricular noncompaction criteria provided, single submitter clinical testing
OMIM RCV000009992 SCV000030213 risk factor Long qt syndrome 3, acquired, susceptibility to 2008-04-15 no assertion criteria provided literature only
OMIM RCV000009993 SCV000030214 pathogenic SUDDEN INFANT DEATH SYNDROME 2008-04-15 no assertion criteria provided literature only
Stanford Center for Inherited Cardiovascular Disease,Stanford University RCV000041615 SCV000280473 uncertain significance not specified 2015-10-15 no assertion criteria provided clinical testing Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. SCN5A p.Ser1103Tyr (c.3308C>A), heterozygous, missense. Also reported in the literature as p.Ser1102Tyr and is catalogued in dbSNP as rs7626962. This is a previously reported variant that is common in African-Americans with allele frequency estimates ranging from 0.056 to 0.101 (Burke et al 2005, Splawski et al 2002, dbSNP). Splawski et al (2002) first reported an association with arrhythmias. They found this variant associated with arrhythmia in African Americans referred to molecular genetic testing centers because of arrhythmia or suspected risk o f arrhythmia. Of the 23 cases, 11 were heterozygotes (47.8%) and 2 were homozygotes (8.7%), while only 13 of the 100 controls were heterozygotes and none were homozygotes. This difference was statistically significant (p = 0.000028). The authors observed statistically significant linkage within one of the case families; all eleven individuals who had a prolonged QTc and/or syncope carried at least one copy of the variant (6 were homozygotes, 5 were heterozygotes). The proband in that family presented with QTc prolongation and Torsades while on amiodarone. The variant has been reported as over-represented in cases of African Americans with arrhythmias, autopsy-negative sudden death in adults and adolescents, and in SIDS (Marjamma et al 2009; Burket et al 2005; Plant et al 2006; Van Norstrand et al 2008). In vitro studies using a whole patch clamp assay showed the variant increased channel activation (Splawski et al 2002). Plant et al (2006) reported a normal in vitro phenotype under standard conditions and an LQT3-like phenotype under low pH. Taken together, these data suggest this variant can confer a mildly increased risk of arrhythmias.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.